Abstract Library

#2119 Positron Emission Tomography (PET) Predictors of Tumor Response to Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors (NET)

Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate (68Ga-DOTATATE) PET standardised uptake value (SUV) has shown conflicting results in the prediction of tumour response to radionuclide therapy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,

Keywords: 68Ga-DOTATATE PET-CT, SUV parameters, Tumor response, Somatostatin receptor tumor volume,

#2069 Tumor Absorbed Dosimetry and Response of Radionuclide Therapy in Metastatic Neuroendocrine Tumor

Introduction: Increased tumour lesion absorbed dosimetry (TLAD) from peptide receptor radionuclide therapy (PRRT) is associated with neuroendocrine tumours (NET) response. Responses to PRRT might be impacted by NET grade, site of origin and use of concurrent chemotherapy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,

Keywords: 68Ga-DOTATATE PET, Tumor Dosimetry, Response,

#2014 Imaging of Advanced Medullary Thyroid Carcinoma with the CCK-2 Receptor Agonist 177Lu-PP-F11N – Preliminary Proof of the Principle within the “Lumed” Study

Introduction: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). Targeting the cholecystokinine-2 (CCK-2) receptor with radiolabeled gastrin analogues is a potential approach for radionuclide therapy of MTC.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Rottenburger C, Nicolas G, McDougall L, Kaul F, Christ E,

Keywords: Medullary thyroid carcinoma, cholecystokinine-2 receptor, radionuclide therapy, theranostics,

#1425 Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate.

Introduction: Lutetium-177 DOTA-octreotate (LuTate), a radiolabelled somatostatin analogue, delivers targeted radiation to neuroendocrine tumours and metastases. Healthy tissues also receive significant irradiation. Charged amino acids are routinely co-infused to block renal proximal tubular LuTate reabsorption. Gelofusine® (a succinylated bovine gelatin molecule), proposed to interact with the megalin/cubulin receptor-mediated transporter system, has been shown to reduce renal uptake of indium-111 octreotide. Routine Gelofusine® administration is limited by risk of allergic reaction.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Lucas C, Goodman S, Smith J, Burge M, Wyld D,

Keywords: lutetium, dosimetry, renal, gelatin, somatostatin,

#1395 A Single Centres Experience of Cardiac Metastasis from Neuroendocrine Tumours (NET)

Introduction: Cardiac metastasis from NET are rare with little information to guide management strategies. Previous case reports discuss varying strategies including observation, somatostatin analogues (SSA), chemotherapy, radiotherapy and resection.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Ladwa R, Burge M, Wyld D,

Keywords: Cardiac metastasis, NET,